Teva Canada announced a commercialization and supply agreement with Novartis Canada for Mayzent® (siponimod), an oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada.
This collaboration leverages Teva's established central nervous system (CNS) expertise and national commercial infrastructure, ensuring continued access to Mayzent® for Canadian patients and healthcare professionals. The agreement is designed to maximize the reach and impact of Mayzent®, building on Teva's established history with neurologists and MS specialists across the country.
"This is about more than a product - it's about people," said Fabien Paquette, General Manager, Teva Canada. "Through this partnership, we are reaffirming our dedication to the MS community and to patient-centred care. Teva Canada is proud to lead with purpose, ensuring access and support for those who need it most. We are all in for better health."
"This agreement reflects our shared responsibility to support people living with MS," said Dimitri Gitas, Country President, Novartis Canada "Through this partnership, we're strengthening support for Canadians living with multiple sclerosis and advancing better health outcomes nationwide."
Mayzent® is indicated in Canada for the treatment of patients with secondary progressive multiple sclerosis (SPMS) with active disease, as evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!